Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of ARGX-113-2009 in Bullous Pemphigoid
2024-515832-59-00Phase 3Completed
- Sponsor
- argenx
- Start
- Oct 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa + hyaluronidase-qvfc in Bullous Pemphigoid (BP), sponsored by argenx. Primary endpoints: Incidence and severity of treatment-emergent adverse events, serious adverse events, and adverse events of special interest and Rate of treatment discontinuation because of safety concerns. Started Oct 2024; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2024-515832-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515832-59-00.